New engineered antibodies against prions.
A number of recently developed and approved therapeutic agents based on highly specific and potent antibodies have shown the potential of antibody therapy. As the next step, antibody-based therapeutics will be bioengineered in a way that they not only bind pathogenic targets but also address other issues, including drug targeting and delivery. For antibodies that are expected to act within brain tissue, like those that are directed against the pathogenic prion protein isoform, one of the major obstacles is the blood-brain barrier which prevents efficient transfer of the antibody, even of the engineered single-chain variants. We recently demonstrated that a specific prion-specific antibody construct which was injected into the murine tail vein can be efficiently transported into brain tissue. The novelty of the work was in that the cell penetrating peptide was used as a linker connecting both specificity-determining domains of the antibody peptide, thus eliminating the need for the standard flexible linker, composed of an arrangement of three consecutive (Gly 4Ser) repeats. This paves the road toward improved bioengineered antibody variants that target brain antigens.
Chair of Biochemistry; Faculty of Chemistry and Chemical Technology; University of Ljubljana; Ljubljana, Slovenia.
Nives
N
Škrlj
Chair of Biochemistry; Faculty of Chemistry and Chemical Technology; University of Ljubljana; Ljubljana, Slovenia.
Marko
M
Dolinar
D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D057846:Cell-Penetrating Peptides / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods*; D008297:Male; D057127:Single-Chain Antibodies / Q000378:metabolism*
D057846:Cell-Penetrating Peptides; D057127:Single-Chain Antibodies
Creutzfeldt-Jakob disease (CJD); blood-brain barrier; cell-penetrating peptides; prion protein; single chain antibody fragment (scFv)